Inovio Pharmaceuticals Inc
NASDAQ:INO
Intrinsic Value
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. [ Read More ]
The intrinsic value of one
INO
stock under the Base Case scenario is
145.25
USD.
Compared to the current market price of 10.37 USD,
Inovio Pharmaceuticals Inc
is
Undervalued by 93%.
Inovio Pharmaceuticals Inc's market capitalization is 236.4m USD.
INO stock price is 10.37 USD.
INO stock price (10.37 USD) is 93% less than its Intrinsic Value (145.25 USD).
INO. Open DCF Valuation
INO stock price (10.37 USD) is 93% less than its Relative Value (145.25 USD). Open Relative Valuation
INO has upside potential of 89% compared to the average analyst price target.
Open Wall St Estimates
INO's Revenue has dropped by 92% over the past 12 months.
INO's ROE (Return on Equity) has significantly decreased in the last 3 years from -49% to -80%, and is approaching profitability.
INO's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -175% to -749%, and is approaching profitability.
INO has negative Operating Income for the last twelve months.
INO has negative Net Income for the last twelve months.
INO's ROE (Return on Equity) for the past 12 months is negative and is equal to -80%.
INO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -749%.
INO's Revenue is forecast to grow at a rate of 476% per year over the next 3 years.
INO has negative Free Cash Flow for the last twelve months.
INO's Revenue has been falling by 52% per year for the last 3 years.
INO's long-term assets (171m USD) exceed its long-term liabilties (54m USD).
INO's short-term assets (153m USD) exceed its short-term liabilties (43m USD).
INO has negative three-year average ROE (Return on Equity): -73%. The company is not efficient at transforming stockholders' equity into net income.
INO has negative three-year average ROIC (Return on Invested Capital): -501%. The company is not efficient at using invested capital to generate operating income.
INO's D/E (Debt to Equity) is very low and is equal to 0.
INO's Altman Z-Score is very low and is equal to -14.54.
INO doesn't generate enough operating income (-133m USD) to safely cover interest payments on its debt (1m USD).
Fundamental Analysis
Inovio Pharmaceuticals Inc
Balance Sheet Decomposition
Inovio Pharmaceuticals Inc
| Current Assets | 153.1m |
| Cash & Short-Term Investments | 145.3m |
| Receivables | 2.4m |
| Other Current Assets | 5.4m |
| Non-Current Assets | 17.8m |
| Long-Term Investments | 2.8m |
| PP&E | 14.5m |
| Other Non-Current Assets | 605.3k |
| Current Liabilities | 42.6m |
| Accounts Payable | 4.6m |
| Accrued Liabilities | 21m |
| Other Current Liabilities | 16.9m |
| Non-Current Liabilities | 11m |
| Other Non-Current Liabilities | 11m |
Earnings Waterfall
Inovio Pharmaceuticals Inc
|
Revenue
|
832k
USD
|
|
Operating Expenses
|
-134.3m
USD
|
|
Operating Income
|
-133.4m
USD
|
|
Other Expenses
|
-1.7m
USD
|
|
Net Income
|
-135.1m
USD
|
Free Cash Flow Analysis
Inovio Pharmaceuticals Inc
What is Free Cash Flow?
INO Profitability Score
Profitability Due Diligence
Inovio Pharmaceuticals Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
Score
Inovio Pharmaceuticals Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
INO Solvency Score
Solvency Due Diligence
Inovio Pharmaceuticals Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Inovio Pharmaceuticals Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INO Price Targets Summary
Inovio Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
INO
is 19.64 USD
with a low forecast of 8.08 USD and a high forecast of 42 USD.
Ownership
INO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
INO Price
Inovio Pharmaceuticals Inc
| Average Annual Return | 17.57% |
| Standard Deviation of Annual Returns | 125.75% |
| Max Drawdown | -99% |
| Market Capitalization | 236.4m USD |
| Shares Outstanding | 23 370 400 |
| Percentage of Shares Shorted | 9.06% |
INO News
Last Important Events
Inovio Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Inovio Pharmaceuticals Inc
Company Profile
Inovio Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 317 full-time employees. The firm is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies (dMAbs and dBTAs), which utilizes the two components of INOVIO's integrated platform, SynCon and CELLECTRA. The firm's SynCon technology creates optimized plasmids. INOVIO's CELLECTRA smart delivery devices facilitate uptake of its DNA medicines into the cell. Its SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses.
You don't have any saved screeners yet
